tions were made: (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classifi cation of Disease for Oncology (ICDO), (2) collect data on all instances of specifi c cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors. We view this conference as part of a continuing process. Because classifi cation of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed. Neuro-Oncology 7, 196-201, 2005 (Posted to Neuro-Oncology [serial online], Doc. 04-050, February 11, 2005 DOI: 10.1215/S115285170400050X) T he registration of tumors of the central nervous system has been a concern for the brain tumor clinical, research, and patient communities as well as for the cancer surveillance community. In 1998, the Brain Tumor Working Group was appointed by the National Coordinating Council for Cancer Surveillance (NCCCS) 3 to investigate the surveillance of primary intracranial and CNS tumors (BTWG, 1998 (McCarthy et al., 2002) . Consensus was reached on a standard defi nition for collecting data on primary brain tumors based on site, as follows (codes for International Classification of Diseases for Oncology [ICDO] are given in parentheses after each site): Primary intracranial and CNS tumors are all primary tumors occurring in the following sites, irrespective of histologic type or behavior: meninges (C70.0-70.9); brain (71.0-C71.9); spinal cord, cranial nerves, and other parts of the central nervous system (72.0-C72.9); pituitary (75.1); craniopharyngeal duct (C75.2); and pineal gland (C75.3). This standard defi nition was used in the Benign Brain Tumor Cancer Registries Amendment Act, which was passed two years later as Public Law 107-260 (2002). Even though Public Law 107-260 only mandated collection of benign and uncertain brain tumors having ICDO codes by the registries participating in the Center for Disease Control's NPCR, all members of NCCCS voluntarily agreed to incorporate these tumors into their collection practices for brain tumors.
is adequately measured and ultimately reduced (Greene, 1997) . Its members include the Centers for Disease Control's National Program of Cancer Registries (NPCR), the National Cancer Institute's Surveillance, Epidemiology, and End Results program, the American College of Surgeons' Commission on Cancer's National Cancer Data Base, and the National Center for Health Statistics. In addition, the American Cancer Society (ACS), the National Cancer Registrars Association (NCRA), the Armed Forces Institute of Pathology (AFIP), and the North American Association of Central Cancer Registries (NAACCR) are members. Development of uniform standards, uniform coding rules, and uniform content are goals of the NCCCS. Because the Central Brain Tumor Registry of the United States (CBTRUS) provides statistical data on all primary brain tumors from state cancer registries that collect data on benign and uncertain as well as malignant brain tumors, the NCCCS decided to access its members' collection of these data to ensure uniformity of standards.
The recommendations formulated by the NCCCS Brain Tumor Working Group included reaching an agreement on the standard defi nition for collecting precise data for all primary intracranial and CNS tumors. To further this goal, CBTRUS convened the Consensus Conference on Brain Tumor Defi nition for Registration (Consensus Conference I) in November 2000, with participants representing surveillance organizations belonging to the NCCCS and those belonging to clinical, research, and professional brain tumor organizations (McCarthy et al., 2002) . Consensus was reached on a standard defi nition for collecting data on primary brain tumors based on site, as follows (codes for International Classification of Diseases for Oncology [ICDO] are given in parentheses after each site): Primary intracranial and CNS tumors are all primary tumors occurring in the following sites, irrespective of histologic type or behavior: meninges (C70.0-70.9); brain (71.0-C71.9); spinal cord, cranial nerves, and other parts of the central nervous system (72.0-C72.9); pituitary (75.1); craniopharyngeal duct (C75.2); and pineal gland (C75.3). This standard defi nition was used in the Benign Brain Tumor Cancer Registries Amendment Act, which was passed two years later as Public Law 107-260 (2002 
Rationale
During the process of reaching consensus on a standard definition for brain tumor registration and formulating implementation guidelines, concerns surfaced about the rules that guide the collection and reporting of all primary brain tumors. Consequently, the Brain Tumor Working Group II and the Registry Operations Committee Benign Brain Tumor Sub-Committee worked in concert to help produce rules for the collection and reporting of benign brain tumors (NAACCR, 2003) . Even though this was the committees' sole charge, they proposed changes to the rules that guide the collection and reporting of malignant brain tumors. These proposed changes have been referred to the Surveillance, Epidemiology, and End Results Site Histology Committee and have not been fi nalized at this time. However, issues regarding topography (site) code changes, the addition of brain-related cysts and tumor-like lesions, and the collection of data on genetic syndromes were beyond the scope of these work groups. The rationale for these proposed changes to data collection is outlined below.
The Benign Brain Tumor Cancer Registries Amendment Act stipulates that primary brain-related tumors located in the sites listed in the brain tumor site definition must also be listed in ICDO (Fritz et al., 2000; Public Law 107-260, 2002) . Clinicians and researchers, especially neuropathologists, realized the full impact of this rule during implementation meetings for the collection of the benign brain tumors by state cancer registries. While many benign tumors, cysts, and tumor-like lesions occurring in brain-related sites are listed in the third edition of ICDO (ICDO-3) (Fritz et al., 2000) , several brain-related cysts and tumor-like lesions deemed important by the brain tumor research and clinical community are listed only in the Systematized Nomenclature of Medicine (SNOMED) of the College of American Pathologists, and a few brain-related cysts and tumorlike lesions are not listed in either ICDO or SNOMED. As such, the brain-related cysts and tumor-like lesions not listed in ICDO would not be reported to the central cancer registries, and this exclusion would prevent an accurate population-based assessment of the distribution of these conditions.
The addition of a new site classifi cation for brain and CNS tumors had been suggested at Consensus Conference I (McCarthy et al., 2002) . Under the current ICDO-3 site classifi cation scheme, meningiomas have three site codes: C70.0 (Cerebral Meninges), C70.1 (Spinal Meninges), and C70.9 (Meninges, NOS) (Fritz et al., 2000) . Meningiomas that are given more specifi c site classifi cations by pathologists, neuropathologists, or clinicians are often coded to the NOS (C70.9) category. A specifi c site code to capture tumors found in the cav-ernous sinus, petrous bone, sphenoid wing, and other skull base sites was recommended, because the capability to collect information on tumors in this site would be benefi cial for clinical research.
Several genetic conditions or syndromes are associated with increased predisposition to the development of certain brain neoplasms. Many of these syndromes, such as neurofi bromatosis 1 and neurofi bromatosis 2, are associated with the occurrence of numerous primary brain tumors in each affected patient; others, such as hereditary nonpolyposis colon cancer (Turcot's syndrome), can be associated with the early onset of malignant brain tumors (Kleihues and Cavenee, 1997; Lindor and Greene, 1998; McLendon and Tien, 1998; Taylor et al., 2001) . Knowledge of the incidence and the personal and fi nancial impact of these inherited syndromes in individuals with brain and CNS tumors is markedly incomplete because it is based on individual hospital case records not captured in statewide data. Although it is likely that initially the data collected on inherited syndromes may not be complete because of incomplete information in the medical records or incomplete data abstraction, the addition of this variable to the reporting requirements would allow investigators to begin to estimate the impact of inherited syndromes in these individuals. Eventually, the standardization of data collection rules and the increased use of this information in diagnosis and treatment will result in the improvement of the accuracy and completeness of these data.
Collection of data on syndromes also provides a resource for researchers to learn about mutations that are common to these syndromes through special study investigations. Information on mutations occurring in these neurogenetic syndromes can contribute to the body of knowledge concerning tumorigenesis of intracranial and other CNS tumors. For example, detailed molecular analyses of the genetic syndromes associated with brain and CNS tumors have "led to the important fi nding that the sequential loss of genetic material plays a signifi cant role in tumorigenesis" (Thapar et al., 1995) . Mutations in tumor suppressor genes associated with specifi c familial syndromes have also been found in sporadic tumors, such as mutations of the NF2 gene in sporadic meningiomas (Bigner et al., 1998) . Therefore, identifying the role of these tumor suppressor genes in tumorigenesis has implications not only for familial disease, but for sporadic tumors as well. Collection of data on inherited syndromes in cancer registries would provide researchers with a valuable resource to obtain information on the genetics of brain and CNS tumors.
Methods
A comprehensive review of ICDO-3 was conducted to identify brain-related cysts and tumor-like lesions currently collected by the central cancer registries (Table  1; Fritz et al., 2000) . After a literature review, a review of SNOMED codes, and discussions with researchers, clinicians, and neuropathologists (Appendix), a comprehensive list of brain-related cysts and tumor-like lesions that do not have ICDO-3 codes was developed.
Results

In November 2003, CBTRUS facilitated the Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors (Consensus Conference II).
Representatives belonging to clinical and research organizations met in Keystone, Colorado, during the Society for Neuro-Oncology Annual Meeting to review the registration of cysts and tumor-like lesions of the brain and the entire CNS, to consider a topography code in ICDO for skull base tumors, and to agree on a list of genetic syndromes associated with CNS tumors. Consensus was achieved on four recommendations.
Recommendation 1
The list of cysts and tumor-like lesions of the brain and CNS that currently are coded in ICDO-3 was reviewed.
Recommendation for a change to the existing morphology coding scheme, specifically that Rathke pouch tumor be given a separate ICDO code rather than be combined with craniopharyngioma (9350/1), was suggested (Table 1) .
Recommendation 2
The collection of additional selected cysts and tumor-like lesions found in brain-related sites but currently lacking ICDO codes was recommended. A list of proposed ICDO codes for these cysts and tumor-like lesions is presented in Table 2 . Participants in the 2003 Consensus Conference II reviewed brain-related cysts and tumorlike lesions having either SNOMED but not ICDO codes or neither SNOMED nor ICDO codes, and they recommended the assignment of ICDO codes to these cysts and tumor-like lesions of the CNS. The proposed codes are based on the participants' review of current ICDO-3 coding assignments (Fritz et al., 2000) .
Recommendation 3
The addition of a new ICDO topography code for skull base tumors (C70.2) was recommended. The proposed code is based on the review by the consensus conference participants of current topography codes listed in ICDO-3 and the importance of accurately capturing tumors of the nervous system with increased topographic specifi city. Recommendations for changes to existing coding are listed in Table 3 .
Recommendation 4
The collection of data on genetic syndromes in persons diagnosed with tumors of the brain and CNS was recommended (Table 4) . Participants in Consensus Con- Nerve root cyst, perineurial cyst, Tarlov cyst 9572/0 *It was agreed that both of the following lesions should be collected and should be grouped with the meningiomas. However, no separate codes are available.
• Meningioangiomatosis
• Arachnoid cyst, leptomeningeal cyst Agreement was also reached that (1) (Fritz et al., 2000) , and will be considered by the IARC Editorial Committee for revisions to the next edition of ICDO. The implications of a new revision of ICDO are wide ranging. Cancer registries worldwide take great care when implementing changes because of issues of geographical comparability and trends over time (Letter from Sharon Whelan, IARC, January 9, 2004). The intent of Recommendations 1 and 2 was discussed with representatives from SNOMED at the American College of Pathology prior to Consensus Conference II, and discussions are ongoing. Recommendation 4 has been sent to the Uniform Data Standards Benign Brain Tumor Sub-committee, who will bring this issue to NCCCS. Because Consensus Conference II was restricted to discussions involving tumors of the brain and CNS, the collection of data on genetic syndromes related to CNS tumors will need to be addressed within the context of the collection of data on genetic syndromes related to all cancer sites. Consensus Conference II is part of a continuum of meetings concerning issues affecting cancer registration of intracranial and other CNS tumors. Classifi cation of these tumors is dynamic, and the registration and coding of these tumors will need to be continually reviewed. The interaction between the cancer registration community and the brain tumor clinical and research community as they worked together to implement the collection of benign brain tumors proved educational for both parties and continues to build on one of the recommendations of Consensus Conference I: to continue this joint effort between the surveillance and clinical communities. Meetings of this nature are part of the process of attaining the fi ve-year research priorities set in 2000 by the Brain Tumor Progress Review Group, a joint effort of the National Cancer Institute and the National Institute of Neurological Disorders and Stroke (Brain Tumor Progress Review Group, 2000) .
